AstraZeneca (AZN)
| Bid | 69.73 |
| Market Cap | 445.24B |
| Revenue (ttm) | 54.98B |
| Net Income (ttm) | 7.77B |
| EPS (ttm) | 2.25 |
| PE Ratio (ttm) | 31.91 |
| Forward PE | 13.28 |
| Analyst | Buy |
| Ask | 69.82 |
| Volume | 3,474,224 |
| Avg. Volume (20D) | 6,252,116 |
| Open | 72.52 |
| Previous Close | 71.71 |
| Day's Range | 71.31 - 72.57 |
| 52-Week Range | 61.24 - 87.68 |
| Beta | 0.25 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardi...
Analyst Forecast
According to 5 analyst ratings, the average rating for AZN stock is "Buy." The 12-month stock price forecast is $95, which is an increase of 32.30% from the latest price.
Stock Forecasts
16 hours ago · proactiveinvestors.co.uk
AstraZeneca has plenty coming down the pipeline to appease the bearsAstraZeneca PLC (LSE:AZN) investors looking beyond the short-term noise of Medicare reform and currency headwinds may want to focus on a growing pipeline of clinical catalysts and a valuation that UBS...
2 days ago · proactiveinvestors.co.uk
AstraZeneca shares claw their way back into green after revenue missAfter an early stumble, AstraZeneca PLC (LSE:AZN) shares pulled back to level by the close on Tuesday, but analysts see reasons for investors to stay watchful despite the apparent strength of the resu...
